Genetic Technologies Gross Profit 2010-2021 | GENE

Genetic Technologies gross profit from 2010 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Genetic Technologies Annual Gross Profit
(Millions of US $)
2021 $-0
2020 $-0
2019 $-0
2018 $-0
2017 $0
2016 $0
2015 $2
2014 $3
2013 $1
2012 $2
2011 $3
2010 $3
2009 $2
Genetic Technologies Quarterly Gross Profit
(Millions of US $)
2021-12-31
2021-06-30
2020-12-31
2020-06-30
2019-12-31
2019-06-30
2018-12-31
2018-06-30
2017-12-31
2017-06-30
2016-12-31
2016-06-30
2015-12-31
2015-06-30
2014-12-31
2014-06-30
2013-12-31
2013-06-30
2012-12-31
2012-06-30
2011-12-31
2011-06-30
2010-12-31
2010-06-30
2009-12-31
2009-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.025B $0.000B
Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $159.141B 9.65
GSK (GSK) United Kingdom $71.077B 8.53
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.276B 18.88
Biohaven Pharmaceutical Holding (BHVN) United States $10.581B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.200B 0.00
Arcus Biosciences (RCUS) United States $2.020B 39.44
Myovant Sciences (MYOV) United Kingdom $1.765B 0.00
Emergent Biosolutions (EBS) United States $1.521B 8.81
Zymeworks (ZYME) Canada $0.418B 0.00
Enzo Biochem (ENZ) United States $0.133B 0.00
Gelesis Holdings (GLS) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
Ambrx Biopharma (AMAM) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00